Janssen acquires over 90% of Actelion
pharmafile | April 24, 2017 | News story | Sales and Marketing | Actelion, Janssen
Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of its shares, according to provisional tender results. The figure represents a total of 99,303,760 of the Swiss pharma and biotech company at $280 each of the 107,339,642 of the shares covered in the tender offer.
Following the deal, Actelion has plans to spin out its drug discovery operations and early-stage clinical development assets by creating a new company, which will be known as Idorsia. Shares from this new venture will be awarded to shareholders of Actelion, which will then be listed on the SIX Swiss Exchange. Because of the tender rate of the deal, Actelion expects to be excluded from the Exchange’s SMI blue-chip index.
The offer is expected to be settled by the second quarter of the year, subject to the satisfaction of the conditions outlined in the tender offer.
The original deal-making process had industry figures watching closely over a period of months as Janssen tenaciously attempted to secure Actelion, which culminated when the former offered the final figure of $30 billion – a sum many believed was an overvaluation, though Janssen sees the move as a key way to expand its rare disease portfolio.
Matt Fellows
Related Content
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …
Janssen submits sNDA to FDA for full approval of Balversa
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …